Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2024
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| - | - | 27.4% |
| 2024 |
|---|
| 27.4% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| - | - | 27.4% |
| 2024 |
|---|
| 27.4% |
Summers Value Fund delivered a strong 27.4% net return in 2024, significantly outperforming both the Russell 2000 Index (11.3%) and Russell 2000 Value Index (7.7%). The fund's concentrated approach focuses on small-cap value opportunities with business quality and positive change factors. Key contributors included Electromed, which appreciated 176% driven by record sales and profits from its respiratory device business, and UFP Technologies, which benefited from acquisitions and its relationship with Intuitive Surgical. The fund also profited from short positions, notably Modivcare. Despite small-cap underperformance continuing in 2024, with large-cap Magnificent 7 stocks driving market gains, the manager maintains conviction that small-caps are well-positioned for outperformance due to lower valuations, poor sentiment, and expected M&A activity under the new administration. The fund currently holds twelve long positions and maintains a selective shorting approach. Since inception, the fund has achieved 12.8% annualized returns versus 6.0% for the Russell 2000.
Small-cap value investing focused on business quality and positive change factors, with conviction that small-cap stocks are well-positioned to outperform large-cap stocks due to lower valuations, poor sentiment, and expected M&A uptick.
Manager remains optimistic that the strategy will continue to deliver above-market returns for investors over the long run, maintaining conviction in small-cap positioning despite recent underperformance.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 30 2025 | 2024 Q4 | AAPL, AMZN, CCSI, ELMD, GOOGL, INDV, ISRG, LFCR, META, MODV, MSFT, NVDA, OTCM, PINC, SPOK, UFPT, UTMD, VSTS, ZBH, ZIMV | Concentration, healthcare, Long/Short, Medical Devices, small caps, value |
ELMD UFPT INDV ZIMV |
Summers Value Fund returned 27.4% in 2024, outperforming small-cap benchmarks through concentrated value investing in quality businesses. Despite continued small-cap underperformance versus large-cap Magnificent 7 stocks, the manager believes small-caps are positioned for outperformance due to attractive valuations, poor sentiment, and expected M&A uptick under new administration. |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2024 Q4 |
Small CapsManager believes small-cap stocks are well-positioned to outperform relative to large-cap stocks going forward, driven by lower valuations, poor sentiment, and an expected uptick in M&A under the new administration. Small-cap stocks furthered a multi-year trend of underperformance in 2024, although the indexes closed positive in absolute terms. |
Valuations M&A Underperformance Sentiment |
Medical DevicesFund holds positions in medical device companies including Electromed (respiratory devices), UFP Technologies (medical device components), and Zimvie (dental implants). Electromed delivered exceptional performance with record sales and profits, while UFP Technologies benefited from its relationship with Intuitive Surgical. |
Respiratory Components Dental Growth | |
ValueThe fund focuses on business quality and positive change factors combined with a long-term investment orientation. Strategy has benefited from identifying undervalued companies with strong fundamentals and improvement potential. |
Quality Change Fundamentals Undervalued |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 1, 2025 | Fund Letters | Summers Value Partners | ZIMV | Zimvie | Health Care Equipment & Supplies | Health Care Equipment | Bull | NASDAQ | acquisition target, balance sheet improvement, Dental-Implants, Medical devices, spin-off, turnaround, undervalued | Login |
| Jan 1, 2025 | Fund Letters | Summers Value Partners | ELMD | Electromed | Health Care Equipment & Supplies | Health Care Equipment | Bull | NASDAQ | Bronchiectasis, growth, Healthcare Equipment, Medical devices, Respiratory Therapy, small-cap, SmartVest | Login |
| Jan 1, 2025 | Fund Letters | Summers Value Partners | UFPT | UFP Technologies | Materials | Specialty Chemicals | Bull | NASDAQ | Acquisitions, deleveraging, Healthcare Components, Intuitive Surgical, Medical Manufacturing, specialty materials, value creation | Login |
| Jan 1, 2025 | Fund Letters | Summers Value Partners | INDV | Indivior | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals | Bull | NASDAQ | contrarian, Long-Acting, Opioid Addiction, pharmaceuticals, Regulatory Approval, Sublocade, underpenetrated market | Login |
| TICKER | COMMENTARY |
|---|---|
| ELMD | We have held Electromed in the Fund since its inception in 2018, and I currently serve on the company's board of directors. The new management team at Electromed delivered an exceptional year in 2024 achieving record sales, profits, and cash flow. As a result, the stock appreciated by 176%. Electromed markets the SmartVest device, which treats the respiratory condition bronchiectasis and has continued to gain share due to its superior product profile and singular focus on this growing market. |
| SPOK | Our top five holdings at year-end included Spok Holdings (SPOK). The Fund received $643,692 of dividend payments in 2024, primarily from our position in Spok Holdings. We trimmed our position in SPOK during the year, which reduced our dividend income relative to 2023. |
| VSTS | Our top five holdings at year-end included Vestis (VSTS). |
| CCSI | Our top five holdings at year-end included Consensus Cloud Solutions (CCSI). |
| ZIMV | Zimvie remains on the detractor list for the second consecutive year. The stock struggled in the second half of the year following acquisition rumors that circulated last summer, which ultimately proved false. We continue to hold our position in Zimvie, as we believe the stock is worth over $20 per share, either in an acquisition scenario or through improvements to revenue growth or margin performance. |
| MODV | The biggest contributor on the short side was Modivcare (MODV), which we successfully shorted twice during the year. The stock declined significantly due to deteriorating business prospects and an overburdened balance sheet, which resulted from a spree of ill-advised acquisitions in 2021. |
| LFCR | We sold most of our Lifecore Biomedical (LFCR) position in the fourth quarter, following several years of disappointing performance that left the company's balance sheet in a state of disrepair. |
| UFPT | UFPT has been a strong performer since we first purchased it in 2020. The company continued its strong performance in 2024, benefiting from its growing relationship with Intuitive Surgical (ISRG). UFPT announced three acquisitions during the year, which we believe will drive further growth from a scale and profitability standpoint. During the year, we trimmed our exposure to UFPT as the stock's valuation increased, and we have now sold 90% of our original position. |
| INDV | In October, we established a position in Indivior after the company reduced its sales forecast for Sublocade, a long-acting buprenorphine drug for the treatment of opioid addiction. Our thesis is that Sublocade's weakness would prove temporary as Indivior has filed a supplemental new drug application (sNDA) for an improved dosing regimen. Our position in Indivior was accumulated at an average cost of $7.74 per share, representing 10x the expected earnings per share for the year. |
| UTMD | Utah Medical is also on our detractor list for the second year in a row. The company's business prospects continued to deteriorate in 2024, falling short of our expectations. The business was negatively impacted by a class action lawsuit related to its Filshie Clip product and the loss of a major customer in the OEM segment. We exited our position during the year, realizing a manageable loss on the investment. |
| PINC | Premier is one of the largest healthcare group purchasing organizations (GPOs) in the US. We purchased Premier in the third quarter of 2023, following the company's announcement of the sale of its non-healthcare GPO business. Despite these positive changes, the company continued to underperform as its core healthcare GPO business faced pricing pressure, and management failed to meet its goal of divesting additional underperforming units. We sold our position at a loss. |
| OTCM | In the fourth quarter, we also received a special dividend of $1.50 per share from OTC Markets (OTCM), totaling $54,543. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||